IDIBELL’s Clinical Trials Research Unit (UICEC), which operates under the direction of the Clinical Pharmacology Service of the Bellvitge University Hospital (HUB) and is led by Dr. Pilar Hereu, has once again obtained ISO 9001:2015 certification. This validation, granted by the Applus+ organization and globally recognized, confirms the excellence of the UICEC’s quality processes, implemented with the support of IDIBELL’s Quality Unit.
The revalidation has been completed without any non-conformity, guaranteeing the quality of the services offered by the UICEC. This certification ranges from the coordination and administrative management of projects to the monitoring and pharmacovigilance of clinical trials.
A key support for clinical research
The UICEC is a fundamental pillar for the clinical research groups of the Bellvitge Campus, offering crucial support for the development of studies and trials in various therapeutic areas. It is especially relevant for researchers, providing them with services that help them assume their responsibilities as independent promoters.
The Unit not only functionally depends on the Clinical Pharmacology Service of the HUB, but is also part of the SCReN (Spanish Clinical Research Network) platform of the Carlos III Health Institute (ISCIII) and the European ECRIN (European Clinical Research Infrastructure Network). Obtaining ISO 9001:2015 reaccreditation reinforces the Unit’s ability to maintain and improve the quality of its services, boosting its offer and its international presence.
The UICEC during 2024
As every year, the Unit has maintained a high level of activity. Specifically, during 2024, the UICEC has supported 31 independently promoted clinical trials. Many of them are national multicentre drug trials with competitive funding.
In addition, the Unit has intensified its international projection, collaborating in global trials that are funded by the H2020 call and supported by the European ECRIN network, as well as with international consortia such as Vaccelerate, which evaluates therapeutic strategies with vaccines against COVID-19, or the TRICALS Foundation, which conducts research into treatment options for Amyotrophic Lateral Sclerosis (ALS).
The Bellvitge Biomedical Research Institute (IDIBELL) is a research centre created in 2004 and specialising in cancer, neuroscience, translational medicine and regenerative medicine. It has a team of more than 1,500 professionals who, from 73 research groups, publish more than 1,400 scientific articles a year. L’IDIBELL is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Health Institute, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.
IDIBELL is a member of the Campus d’Excelencia Internacional of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centres accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the HR Excellence in Research program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Centre of the AECC Scientific Foundation (FCAECC).